Is there a link to the list of panelists? There was a very tough reviewer on the levp panel and i'm curious if he's on this one as well. If so, he'll dominate the discussion in a very negative way.
DYAX – I don't even know what the story on the drug is.
The DX-88 story is long and tortuous. Throughout 2004, DYAX tried to scam investors into believing the FDA would approve DX-88 based on only the phase-2 results (#msg-5061316). GENZ once owned half of the DX-88 program, but they gave up their stake in the program for essentially nothing.
Market Data 
Markets 
AI
